NCT02254434View on ClinicalTrials.gov

A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

August 28, 2014

Primary Completion Date

September 8, 2014

Study Completion Date

September 8, 2014

Conditions

Cirrhosis, Liver

Interventions

DRUG

Eltrombopag

Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally

Trial Locations (1)

14610

GSK Investigational Site, Mexico City

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT02254434 - A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions | Biotech Hunter | Biotech Hunter